{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:57:46Z","timestamp":1789909066570,"version":"4.0.1"},"publisher-location":"Cham","reference-count":96,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319225418","type":"print"},{"value":"9783319225425","type":"electronic"}],"license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015]]},"DOI":"10.1007\/978-3-319-22542-5_10","type":"book-chapter","created":{"date-parts":[[2015,10,22]],"date-time":"2015-10-22T10:38:24Z","timestamp":1445510304000},"page":"207-225","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Long-Term Follow-up in Medullary Thyroid Carcinoma"],"prefix":"10.1007","author":[{"given":"Friedhelm","family":"Raue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Frank-Raue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,23]]},"reference":[{"issue":"11","key":"10_CR1","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/j.1445-2197.2010.05350.x","volume":"80","author":"D Abraham","year":"2010","unstructured":"Abraham D, Delbridge L, Clifton-Bligh R, Clifton-Bligh P, Grodski S, Robinson BG et al (2010) Medullary thyroid carcinoma presenting with an initial CEA elevation. ANZ J Surg 80(11):831\u2013833","journal-title":"ANZ J Surg"},{"issue":"11","key":"10_CR2","doi-asserted-by":"publisher","first-page":"6077","DOI":"10.1210\/jc.2005-0044","volume":"90","author":"Barbet J, Campion L, Kraeber-Bodere F, Chatal JF, Group GTES","year":"2005","unstructured":"Barbet J, Campion L, Kraeber-Bodere F, Chatal JF, Group GTES (2005) Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 90(11):6077\u20136084","journal-title":"J Clin Endocrinol Metab"},{"key":"10_CR3","doi-asserted-by":"crossref","unstructured":"Brierley JD, Tsang RW (2008) External beam radiation therapy for thyroid cancer. Endocrinol Metab Clin N Am 37(2):497\u2013509 (xi)","DOI":"10.1016\/j.ecl.2008.02.001"},{"issue":"4","key":"10_CR4","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1089\/thy.1996.6.305","volume":"6","author":"J Brierley","year":"1996","unstructured":"Brierley J, Tsang R, Simpson WJ, Gospodarowicz M, Sutcliffe S, Panzarella T (1996) Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid Official J Am Thyroid Assoc 6(4):305\u2013310","journal-title":"Thyroid Official J Am Thyroid Assoc"},{"issue":"3","key":"10_CR5","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.4081\/rt.2013.e37","volume":"5","author":"JA Call","year":"2013","unstructured":"Call JA, Caudill JS, McIver B, Foote RL (2013) A role for radiotherapy in the management of advanced medullary thyroid carcinoma: the mayo clinic experience. Rare Tumors 5(3):e37","journal-title":"Rare Tumors"},{"issue":"11","key":"10_CR6","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1200\/JCO.2005.04.4917","volume":"24","author":"JF Chatal","year":"2006","unstructured":"Chatal JF, Campion L, Kraeber-Bodere F, Bardet S, Vuillez JP, Charbonnel B et al (2006) Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol Official J Am Soc Clin Oncol 24(11):1705\u20131711","journal-title":"J Clin Oncol Official J Am Soc Clin Oncol"},{"issue":"5","key":"10_CR7","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1097\/SLA.0b013e31813e66b9","volume":"246","author":"K Cupisti","year":"2007","unstructured":"Cupisti K, Wolf A, Raffel A, Schott M, Miersch D, Yang Q et al (2007) Long-term clinical and biochemical follow-up in medullary thyroid carcinoma: a single institution\u2019s experience over 20\u00a0years. Ann Surg 246(5):815\u2013821","journal-title":"Ann Surg"},{"issue":"6","key":"10_CR8","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/j.1365-2265.2006.02659.x","volume":"65","author":"JW de Groot","year":"2006","unstructured":"de Groot JW, Plukker JT, Wolffenbuttel BH, Wiggers T, Sluiter WJ, Links TP (2006) Determinants of life expectancy in medullary thyroid cancer: age does not matter. Clin Endocrinol 65(6):729\u2013736","journal-title":"Clin Endocrinol"},{"issue":"9","key":"10_CR9","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1210\/jc.2007-0649","volume":"92","author":"JW de Groot","year":"2007","unstructured":"de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, de Vries MM, Links TP, Lips CJ et al (2007) A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 92(9):3466\u20133469","journal-title":"J Clin Endocrinol Metab"},{"issue":"1\u20132","key":"10_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.mce.2007.12.016","volume":"284","author":"S Dvorakova","year":"2008","unstructured":"Dvorakova S, Vaclavikova E, Sykorova V, Vcelak J, Novak Z, Duskova J et al (2008) Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas. Mol Cell Endocrinol 284(1\u20132):21\u201327","journal-title":"Mol Cell Endocrinol"},{"issue":"8","key":"10_CR11","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/nrendo.2012.38","volume":"8","author":"R Elisei","year":"2012","unstructured":"Elisei R, Pinchera A (2012) Advances in the follow-up of differentiated or medullary thyroid cancer. Nat Rev Endocrinol 8(8):466\u2013475","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"10_CR12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1210\/jc.2003-030550","volume":"89","author":"R Elisei","year":"2004","unstructured":"Elisei R, Bottici V, Luchetti F, Di Coscio G, Romei C, Grasso L et al (2004) Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 89(1):163\u2013168","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10_CR13","doi-asserted-by":"publisher","first-page":"4725","DOI":"10.1210\/jc.2007-1005","volume":"92","author":"R Elisei","year":"2007","unstructured":"Elisei R, Romei C, Cosci B, Agate L, Bottici V, Molinaro E et al (2007) RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab 92(12):4725\u20134729","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10_CR14","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1210\/jc.2007-1714","volume":"93","author":"R Elisei","year":"2008","unstructured":"Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E et al (2008) Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 93(3):682\u2013687","journal-title":"J Clin Endocrinol Metab"},{"issue":"29","key":"10_CR15","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","volume":"31","author":"R Elisei","year":"2013","unstructured":"Elisei R, Schlumberger MJ, Muller SP, Schoffski P, Brose MS, Shah MH et al (2013) Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol Official J Am Soc Clin Oncol 31(29):3639\u20133646","journal-title":"J Clin Oncol Official J Am Soc Clin Oncol"},{"issue":"3","key":"10_CR16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/gcc.2870120308","volume":"12","author":"C Eng","year":"1995","unstructured":"Eng C, Mulligan LM, Smith DP, Healey CS, Frilling A, Raue F et al (1995) Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma. Genes Chromosomes Cancer 12(3):209\u2013212","journal-title":"Genes Chromosomes Cancer"},{"issue":"5","key":"10_CR17","first-page":"1890","volume":"85","author":"M Engelbach","year":"2000","unstructured":"Engelbach M, Gorges R, Forst T, Pfutzner A, Dawood R, Heerdt S et al (2000) Improved diagnostic methods in the follow-up of medullary thyroid carcinoma by highly specific calcitonin measurements. J Clin Endocrinol Metab 85(5):1890\u20131894","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10_CR18","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1007\/s00268-007-9317-7","volume":"32","author":"E Fialkowski","year":"2008","unstructured":"Fialkowski E, DeBenedetti M, Moley J (2008) Long-term outcome of reoperations for medullary thyroid carcinoma. World J Surg 32(5):754\u2013765","journal-title":"World J Surg"},{"issue":"3","key":"10_CR19","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1046\/j.1365-2265.2001.01339.x","volume":"55","author":"S Franc","year":"2001","unstructured":"Franc S, Niccoli-Sire P, Cohen R, Bardet S, Maes B, Murat A et al (2001) Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma. Clin Endocrinol 55(3):403\u2013409","journal-title":"Clin Endocrinol"},{"issue":"2","key":"10_CR20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1530\/eje.1.02216","volume":"155","author":"K Frank-Raue","year":"2006","unstructured":"Frank-Raue K, Buhr H, Dralle H, Klar E, Senninger N, Weber T et al (2006) Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype. Eur J Endocrinol Eur Fed Endocr Soc 155(2):229\u2013236","journal-title":"Eur J Endocrinol Eur Fed Endocr Soc"},{"issue":"2","key":"10_CR21","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1530\/EJE-06-0695","volume":"157","author":"K Frank-Raue","year":"2007","unstructured":"Frank-Raue K, Fabel M, Delorme S, Haberkorn U, Raue F (2007) Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. Eur J Endocrinol\/Eur Fed Endocr Soc 157(2):215\u2013220","journal-title":"Eur J Endocrinol\/Eur Fed Endocr Soc"},{"issue":"7","key":"10_CR22","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1210\/jc.2005-2401","volume":"91","author":"J Fromigue","year":"2006","unstructured":"Fromigue J, De Baere T, Baudin E, Dromain C, Leboulleux S, Schlumberger M (2006) Chemoembolization for liver metastases from medullary thyroid carcinoma. J Clin Endocrinol Metab 91(7):2496\u20132499","journal-title":"J Clin Endocrinol Metab"},{"key":"10_CR23","doi-asserted-by":"crossref","unstructured":"Gimm O, Dralle H (1997) Reoperation in metastasizing medullary thyroid carcinoma: is a tumor stage-oriented approach justified? Surgery 122(6):1124\u20131130 (discussion 30\u20131)","DOI":"10.1016\/S0039-6060(97)90217-8"},{"issue":"11","key":"10_CR24","doi-asserted-by":"publisher","first-page":"4185","DOI":"10.1210\/jc.2007-1211","volume":"92","author":"AL Giraudet","year":"2007","unstructured":"Giraudet AL, Vanel D, Leboulleux S, Auperin A, Dromain C, Chami L et al (2007) Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab 92(11):4185\u20134190","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10_CR25","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1210\/jc.2002-021354","volume":"88","author":"L Gourgiotis","year":"2003","unstructured":"Gourgiotis L, Sarlis NJ, Reynolds JC, VanWaes C, Merino MJ, Pacak K (2003) Localization of medullary thyroid carcinoma metastasis in a multiple endocrine neoplasia type 2A patient by 6-[18F]-fluorodopamine positron emission tomography. J Clin Endocrinol Metab 88(2):637\u2013641","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10_CR26","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1210\/jc.2014-4153","volume":"100","author":"EG Grubbs","year":"2015","unstructured":"Grubbs EG, Ng PK, Bui J, Busaidy NL, Chen K, Lee JE et al (2015) RET Fusion as a Novel Driver of Medullary Thyroid Carcinoma. J Clin Endocrinol Metab 100(3):788\u2013793","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10_CR27","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s002590000404","volume":"28","author":"S Hoegerle","year":"2001","unstructured":"Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E (2001) 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nuc Med 28(1):64\u201371","journal-title":"Eur J Nuc Med"},{"issue":"2","key":"10_CR28","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1677\/erc.0.0110357","volume":"11","author":"SI Ismailov","year":"2004","unstructured":"Ismailov SI, Piulatova NR (2004) Postoperative calcitonin study in medullary thyroid carcinoma. Endocr Relat Cancer 11(2):357\u2013363","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"10_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2169\/internalmedicine.38.17","volume":"38","author":"T Isozaki","year":"1999","unstructured":"Isozaki T, Kiba T, Numata K, Saito S, Shimamura T, Kitamura T et al (1999) Medullary thyroid carcinoma with multiple hepatic metastases: treatment with transcatheter arterial embolization and percutaneous ethanol injection. Intern Med 38(1):17\u201321","journal-title":"Intern Med"},{"issue":"22 Pt 1","key":"10_CR30","doi-asserted-by":"publisher","first-page":"6696","DOI":"10.1158\/1078-0432.CCR-07-0935","volume":"13","author":"F Iten","year":"2007","unstructured":"Iten F, Muller B, Schindler C, Rochlitz C, Oertli D, Macke HR et al (2007) Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res Official J Am Assoc Cancer Res 13(22 Pt 1):6696\u20136702","journal-title":"Clin Cancer Res Official J Am Assoc Cancer Res"},{"issue":"8","key":"10_CR31","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1001\/archsurg.135.8.895","volume":"135","author":"E Kebebew","year":"2000","unstructured":"Kebebew E, Kikuchi S, Duh QY, Clark OH (2000a) Long-term results of reoperation and localizing studies in patients with persistent or recurrent medullary thyroid cancer. Arch Surg 135(8):895\u2013901","journal-title":"Arch Surg"},{"issue":"5","key":"10_CR32","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1139::AID-CNCR26>3.0.CO;2-Z","volume":"88","author":"E Kebebew","year":"2000","unstructured":"Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH (2000b) Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 88(5):1139\u20131148","journal-title":"Cancer"},{"issue":"4","key":"10_CR33","first-page":"524","volume":"49","author":"KP Koopmans","year":"2008","unstructured":"Koopmans KP, de Groot JW, Plukker JT, de Vries EG, Kema IP, Sluiter WJ et al (2008) 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J Nucl Med Official Publ Soc Nucl Med 49(4):524\u2013531","journal-title":"J Nucl Med Official Publ Soc Nucl Med"},{"key":"10_CR34","doi-asserted-by":"crossref","unstructured":"Kouvaraki MA, Shapiro SE, Fornage BD, Edeiken-Monro BS, Sherman SI, Vassilopoulou-Sellin R et al (2003) Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery 134(6):946\u2013954 (discussion 54\u20135)","DOI":"10.1016\/S0039-6060(03)00424-0"},{"issue":"2","key":"10_CR35","first-page":"247","volume":"47","author":"F Kraeber-Bodere","year":"2006","unstructured":"Kraeber-Bodere F, Rousseau C, Bodet-Milin C, Ferrer L, Faivre-Chauvet A, Campion L et al (2006) Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. J Nucl Med Official Publ Soc Nucl Med 47(2):247\u2013255","journal-title":"J Nucl Med Official Publ Soc Nucl Med"},{"issue":"19","key":"10_CR36","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1200\/JCO.2010.32.4145","volume":"29","author":"R Kurzrock","year":"2011","unstructured":"Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R et al (2011) Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol Official J Am Soc Clin Oncol 29(19):2660\u20132666","journal-title":"J Clin Oncol Official J Am Soc Clin Oncol"},{"issue":"14","key":"10_CR37","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1200\/JCO.2009.25.0068","volume":"28","author":"ET Lam","year":"2010","unstructured":"Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J et al (2010) Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol Official J Am Soc Clin Oncol 28(14):2323\u20132330","journal-title":"J Clin Oncol Official J Am Soc Clin Oncol"},{"key":"10_CR38","doi-asserted-by":"crossref","unstructured":"Laure Giraudet A, Al Ghulzan A, Auperin A, Leboulleux S, Chehboun A, Troalen F et al (2008) Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol Eur Fed Endocr Soc 158(2):239\u2013246","DOI":"10.1530\/EJE-07-0667"},{"issue":"2","key":"10_CR39","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1089\/thy.2014.0277","volume":"25","author":"SC Lindsey","year":"2015","unstructured":"Lindsey SC, Ganly I, Palmer F, Tuttle RM (2015) Response to initial therapy predicts clinical outcomes in medullary thyroid cancer. Thyroid Official J Am Thyroid Assoc 25(2):242\u2013249","journal-title":"Thyroid Official J Am Thyroid Assoc"},{"key":"10_CR40","doi-asserted-by":"crossref","unstructured":"Lorenz K, Brauckhoff M, Behrmann C, Sekulla C, Ukkat J, Brauckhoff K et al (2005) Selective arterial chemoembolization for hepatic metastases from medullary thyroid carcinoma. Surgery 138(6):986\u2013993 (discussion 93)","DOI":"10.1016\/j.surg.2005.09.020"},{"issue":"6","key":"10_CR41","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1210\/jc.2009-2368","volume":"95","author":"A Machens","year":"2010","unstructured":"Machens A, Dralle H (2010) Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab 95(6):2655\u20132663","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10_CR42","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/SLA.0b013e318268301d","volume":"257","author":"A Machens","year":"2013","unstructured":"Machens A, Dralle H (2013a) Prognostic impact of N staging in 715 medullary thyroid cancer patients: proposal for a revised staging system. Ann Surg 257(2):323\u2013329","journal-title":"Ann Surg"},{"issue":"4","key":"10_CR43","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1097\/SLA.0b013e31826bc239","volume":"257","author":"A Machens","year":"2013","unstructured":"Machens A, Dralle H (2013b) Benefit-risk balance of reoperation for persistent medullary thyroid cancer. Ann Surg 257(4):751\u2013757","journal-title":"Ann Surg"},{"issue":"16","key":"10_CR44","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1056\/NEJMoa012915","volume":"349","author":"A Machens","year":"2003","unstructured":"Machens A, Niccoli-Sire P, Hoegel J, Frank-Raue K, van Vroonhoven TJ, Roeher HD et al (2003) Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 349(16):1517\u20131525","journal-title":"N Engl J Med"},{"issue":"4","key":"10_CR45","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1210\/jc.2004-1836","volume":"90","author":"A Machens","year":"2005","unstructured":"Machens A, Schneyer U, Holzhausen HJ, Dralle H (2005) Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab 90(4):2029\u20132034","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10_CR46","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/j.1365-2265.1990.tb00490.x","volume":"33","author":"C Mahler","year":"1990","unstructured":"Mahler C, Verhelst J, de Longueville M, Harris A (1990) Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide. Clin Endocrinol 33(2):261\u2013269","journal-title":"Clin Endocrinol"},{"issue":"6","key":"10_CR47","first-page":"1241","volume":"56","author":"DJ Marsh","year":"1996","unstructured":"Marsh DJ, Andrew SD, Eng C, Learoyd DL, Capes AG, Pojer R et al (1996a) Germline and somatic mutations in an oncogene: RET mutations in inherited medullary thyroid carcinoma. Cancer Res 56(6):1241\u20131243","journal-title":"Cancer Res"},{"issue":"3","key":"10_CR48","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1046\/j.1365-2265.1996.681503.x","volume":"44","author":"DJ Marsh","year":"1996","unstructured":"Marsh DJ, Learoyd DL, Andrew SD, Krishnan L, Pojer R, Richardson AL et al (1996b) Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol 44(3):249\u2013257","journal-title":"Clin Endocrinol"},{"issue":"2","key":"10_CR49","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/jso.21557","volume":"102","author":"SR Martinez","year":"2010","unstructured":"Martinez SR, Beal SH, Chen A, Chen SL, Schneider PD (2010) Adjuvant external beam radiation for medullary thyroid carcinoma. J Surg Oncol 102(2):175\u2013178","journal-title":"J Surg Oncol"},{"issue":"4","key":"10_CR50","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/j.1365-2265.2009.03666.x","volume":"72","author":"JA Meijer","year":"2010","unstructured":"Meijer JA, le Cessie S, van den Hout WB, Kievit J, Schoones JW, Romijn JA et al (2010) Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis. Clin Endocrinol 72(4):534\u2013542","journal-title":"Clin Endocrinol"},{"issue":"6","key":"10_CR51","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1530\/EJE-11-0079","volume":"164","author":"C Mian","year":"2011","unstructured":"Mian C, Pennelli G, Barollo S, Cavedon E, Nacamulli D, Vianello F et al (2011) Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification. Eur J Endocrinol Eur Fed Endocr Soc 164(6):971\u2013976","journal-title":"Eur J Endocrinol Eur Fed Endocr Soc"},{"issue":"2","key":"10_CR52","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1210\/jc.2004-1500","volume":"90","author":"E Mirallie","year":"2005","unstructured":"Mirallie E, Vuillez JP, Bardet S, Frampas E, Dupas B, Ferrer L et al (2005) High frequency of bone\/bone marrow involvement in advanced medullary thyroid cancer. J clin Endocrinol Metab 90(2):779\u2013788","journal-title":"J clin Endocrinol Metab"},{"issue":"3","key":"10_CR53","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1046\/j.1365-2265.1998.00392.x","volume":"48","author":"E Modigliani","year":"1998","unstructured":"Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A et al (1998) Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d\u2019etude des tumeurs a calcitonine. Clin Endocrinol 48(3):265\u2013273","journal-title":"Clin Endocrinol"},{"issue":"5","key":"10_CR54","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1007\/s00268-006-0846-2","volume":"31","author":"JF Moley","year":"2007","unstructured":"Moley JF, Fialkowski EA (2007) Evidence-based approach to the management of sporadic medullary thyroid carcinoma. World J Surg 31(5):946\u2013956","journal-title":"World J Surg"},{"issue":"11","key":"10_CR55","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1038\/sj.bjc.6605056","volume":"100","author":"MM Moura","year":"2009","unstructured":"Moura MM, Cavaco BM, Pinto AE, Domingues R, Santos JR, Cid MO et al (2009) Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. Br J Cancer 100(11):1777\u20131783","journal-title":"Br J Cancer"},{"issue":"4","key":"10_CR56","first-page":"501","volume":"48","author":"SC Ong","year":"2007","unstructured":"Ong SC, Schoder H, Patel SG, Tabangay-Lim IM, Doddamane I, Gonen M et al (2007) Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med Official Publ Soc Nucl Med 48(4):501\u2013507","journal-title":"J Nucl Med Official Publ Soc Nucl Med"},{"issue":"8","key":"10_CR57","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/oxfordjournals.annonc.a058984","volume":"5","author":"F Orlandi","year":"1994","unstructured":"Orlandi F, Caraci P, Berruti A, Puligheddu B, Pivano G, Dogliotti L et al (1994) Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer. Ann Oncol Official J Eur Soc Med Oncol\/ESMO 5(8):763\u2013765","journal-title":"Ann Oncol Official J Eur Soc Med Oncol\/ESMO"},{"issue":"12","key":"10_CR58","doi-asserted-by":"publisher","first-page":"4590","DOI":"10.1210\/jc.2007-0938","volume":"92","author":"A Oudoux","year":"2007","unstructured":"Oudoux A, Salaun PY, Bournaud C, Campion L, Ansquer C, Rousseau C et al (2007) Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy. J Clin Endocrinol Metab 92(12):4590\u20134597","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10_CR59","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.clon.2010.05.002","volume":"22","author":"F Pacini","year":"2010","unstructured":"Pacini F, Castagna MG, Cipri C, Schlumberger M (2010) Medullary thyroid carcinoma. Clin Oncol 22(6):475\u2013485","journal-title":"Clin Oncol"},{"issue":"1","key":"10_CR60","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1089\/thy.2014.0241","volume":"25","author":"K Pak","year":"2015","unstructured":"Pak K, Suh S, Kim SJ, Kim IJ (2015) Prognostic value of genetic mutations in thyroid cancer: a meta-analysis. Thyroid Official J Am Thyroid Assoc 25(1):63\u201370","journal-title":"Thyroid Official J Am Thyroid Assoc"},{"issue":"10","key":"10_CR61","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1038\/sj.bjc.6600930","volume":"88","author":"G Pellegriti","year":"2003","unstructured":"Pellegriti G, Leboulleux S, Baudin E, Bellon N, Scollo C, Travagli JP et al (2003) Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging. Br J Cancer 88(10):1537\u20131542","journal-title":"Br J Cancer"},{"issue":"2","key":"10_CR62","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1089\/thy.2010.0248","volume":"22","author":"GM Quan","year":"2012","unstructured":"Quan GM, Pointillart V, Palussiere J, Bonichon F (2012) Multidisciplinary treatment and survival of patients with vertebral metastases from thyroid carcinoma. Thyroid Official J Am Thyroid Assoc 22(2):125\u2013130","journal-title":"Thyroid Official J Am Thyroid Assoc"},{"key":"10_CR63","doi-asserted-by":"crossref","unstructured":"Rambaud JC, Jian R, Flourie B, Hautefeuille M, Salmeron M, Thuillier F et al (1988) Pathophysiological study of diarrhoea in a patient with medullary thyroid carcinoma. Evidence against a secretory mechanism and for the role of shortened colonic transit time. Gut 29(4):537\u2013543","DOI":"10.1136\/gut.29.4.537"},{"issue":"5","key":"10_CR64","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s004230050143","volume":"383","author":"F Raue","year":"1998","unstructured":"Raue F (1998) German medullary thyroid carcinoma\/multiple endocrine neoplasia registry. German MTC\/MEN Study Group. Medullary thyroid carcinoma\/multiple endocrine neoplasia type 2. Langenbeck\u2018s Arch Surg Deut Ges fur Chir 383(5):334\u2013336","journal-title":"Langenbeck\u2018s Arch Surg Deut Ges fur Chir"},{"issue":"3","key":"10_CR65","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/j.1365-2265.2008.03229.x","volume":"69","author":"G Rendl","year":"2008","unstructured":"Rendl G, Manzl M, Hitzl W, Sungler P, Pirich C (2008) Long-term prognosis of medullary thyroid carcinoma. Clin Endocrinol 69(3):497\u2013505","journal-title":"Clin Endocrinol"},{"issue":"6","key":"10_CR66","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1210\/jc.2009-2461","volume":"95","author":"BG Robinson","year":"2010","unstructured":"Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R (2010) Vandetanib (100\u00a0mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 95(6):2664\u20132671","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10_CR67","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1002\/cncr.22244","volume":"107","author":"S Roman","year":"2006","unstructured":"Roman S, Lin R, Sosa JA (2006) Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 107(9):2134\u20132142","journal-title":"Cancer"},{"issue":"4","key":"10_CR68","first-page":"1619","volume":"81","author":"C Romei","year":"1996","unstructured":"Romei C, Elisei R, Pinchera A, Ceccherini I, Molinaro E, Mancusi F et al (1996) Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab 81(4):1619\u20131622","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10_CR69","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1245\/s10434-014-4102-y","volume":"22","author":"KJ Rowland","year":"2015","unstructured":"Rowland KJ, Jin LX, Moley JF (2015) Biochemical cure after reoperations for medullary thyroid carcinoma: a meta-analysis. Ann Surg Oncol 22(1):96\u2013102","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10_CR70","first-page":"581","volume":"34","author":"D Rubello","year":"2008","unstructured":"Rubello D, Rampin L, Nanni C, Banti E, Ferdeghini M, Fanti S et al (2008) The role of 18F-FDG PET\/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 34(5):581\u2013586","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"issue":"1","key":"10_CR71","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1530\/EJE-14-0076","volume":"171","author":"K Saltiki","year":"2014","unstructured":"Saltiki K, Rentziou G, Stamatelopoulos K, Georgiopoulos G, Stavrianos C, Lambrinoudaki E et al (2014) Small medullary thyroid carcinoma: post-operative calcitonin rather than tumour size predicts disease persistence and progression. Eur J Endocrinol Eur Fed Endocr Soc 171(1):117\u2013126","journal-title":"Eur J Endocrinol Eur Fed Endocr Soc"},{"issue":"8","key":"10_CR72","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1089\/thy.2007.0179","volume":"18","author":"L Santarpia","year":"2008","unstructured":"Santarpia L, El-Naggar AK, Sherman SI, Hymes SR, Gagel RF, Shaw S et al (2008) Four patients with cutaneous metastases from medullary thyroid cancer. Thyroid Official J Am Thyroid Assoc 18(8):901\u2013905","journal-title":"Thyroid Official J Am Thyroid Assoc"},{"issue":"6","key":"10_CR73","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1111\/cen.12566","volume":"81","author":"P Santhanam","year":"2014","unstructured":"Santhanam P, Taieb D (2014) Role of (18) F-FDOPA PET\/CT imaging in endocrinology. Clin Endocrinol 81(6):789\u2013798","journal-title":"Clin Endocrinol"},{"issue":"1","key":"10_CR74","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/BF01612635","volume":"116","author":"H Scherubl","year":"1990","unstructured":"Scherubl H, Raue F, Ziegler R (1990) Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study. J Cancer Res Clin Oncol 116(1):21\u201323","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"10_CR75","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/1097-0215(20010120)95:1<62::AID-IJC1011>3.0.CO;2-1","volume":"95","author":"T Schilling","year":"2001","unstructured":"Schilling T, Burck J, Sinn HP, Clemens A, Otto HF, Hoppner W et al (2001) Prognostic value of codon 918 (ATG\u2013\u00a0>\u00a0ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. Int J Cancer (J Int du Cancer) 95(1):62\u201366","journal-title":"Int J Cancer (J Int du Cancer)"},{"issue":"2","key":"10_CR76","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/bjc.1995.73","volume":"71","author":"M Schlumberger","year":"1995","unstructured":"Schlumberger M, Abdelmoumene N, Delisle MJ, Couette JE (1995) Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d\u2019Etude des Tumeurs a Calcitonine (GETC). Br J Cancer 71(2):363\u2013365","journal-title":"Br J Cancer"},{"issue":"23","key":"10_CR77","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1200\/JCO.2008.18.7815","volume":"27","author":"MJ Schlumberger","year":"2009","unstructured":"Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD et al (2009) Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol Official J Am Soc Clin Oncol 27(23):3794\u20133801","journal-title":"J Clin Oncol Official J Am Soc Clin Oncol"},{"issue":"7","key":"10_CR78","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/hed.20791","volume":"30","author":"DL Schwartz","year":"2008","unstructured":"Schwartz DL, Rana V, Shaw S, Yazbeck C, Ang KK, Morrison WH et al (2008) Postoperative radiotherapy for advanced medullary thyroid cancer\u2013local disease control in the modern era. Head Neck 30(7):883\u2013888","journal-title":"Head Neck"},{"key":"10_CR79","doi-asserted-by":"crossref","unstructured":"Terezakis SA, Lee NY (2010) The role of radiation therapy in the treatment of medullary thyroid cancer. J Natl Compr Cancer Netw JNCCN 8(5):532\u2013540 (quiz 41)","DOI":"10.6004\/jnccn.2010.0041"},{"issue":"3","key":"10_CR80","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205\u2013216","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10_CR81","first-page":"549","volume":"23","author":"I Vainas","year":"2004","unstructured":"Vainas I, Koussis C, Pazaitou-Panayiotou K, Drimonitis A, Chrisoulidou A, Iakovou I et al (2004) Somatostatin receptor expression in vivo and response to somatostatin analog therapy with or without other antineoplastic treatments in advanced medullary thyroid carcinoma. J Exp Clin Cancer Res CR 23(4):549\u2013559","journal-title":"J Exp Clin Cancer Res CR"},{"issue":"12","key":"10_CR82","first-page":"1863","volume":"53","author":"HH Verbeek","year":"2012","unstructured":"Verbeek HH, Plukker JT, Koopmans KP, de Groot JW, Hofstra RM, Muller Kobold AC et al (2012) Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma. J Nucl Med Official Publ Soc Nucl Med 53(12):1863\u20131871","journal-title":"J Nucl Med Official Publ Soc Nucl Med"},{"issue":"4","key":"10_CR83","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1245\/s10434-014-4115-6","volume":"22","author":"HH Verbeek","year":"2015","unstructured":"Verbeek HH, Meijer JA, Zandee WT, Kramp KH, Sluiter WJ, Smit JW et al (2015) Fewer cancer reoperations for medullary thyroid cancer after initial surgery according to ATA guidelines. Ann Surg Oncol 22(4):1207\u20131213","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10_CR84","first-page":"983","volume":"85","author":"G Vitale","year":"2000","unstructured":"Vitale G, Tagliaferri P, Caraglia M, Rampone E, Ciccarelli A, Bianco AR et al (2000) Slow release lanreotide in combination with interferon-alpha2b in the treatment of symptomatic advanced medullary thyroid carcinoma. J Clin Endocrinol Metab 85(3):983\u2013988","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10_CR85","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1054\/bjoc.2001.1832","volume":"84","author":"G Vitale","year":"2001","unstructured":"Vitale G, Fonderico F, Martignetti A, Caraglia M, Ciccarelli A, Nuzzo V et al (2001) Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer. Br J Cancer 84(12):1586\u20131590","journal-title":"Br J Cancer"},{"key":"10_CR86","doi-asserted-by":"crossref","unstructured":"Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF et al (2015) Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma The American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. Thyroid : official journal of the American Thyroid Association","DOI":"10.1089\/thy.2014.0335"},{"issue":"5","key":"10_CR87","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1210\/jc.2013-2622","volume":"99","author":"SA Wells Jr","year":"2014","unstructured":"Wells SA Jr, Santoro M (2014) Update: the status of clinical trials with kinase inhibitors in thyroid cancer. J Clin Endocrinol Metab 99(5):1543\u20131555","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10_CR88","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1200\/JCO.2009.23.6604","volume":"28","author":"SA Wells Jr","year":"2010","unstructured":"Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA et al (2010) Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol Official J Am Soc Clin Oncol 28(5):767\u2013772","journal-title":"J Clin Oncol Official J Am Soc Clin Oncol"},{"key":"10_CR89","doi-asserted-by":"crossref","unstructured":"Wells SAJ, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF et al (2015) Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma. Thyroid Official J Am Thyroid Assoc 25(6):567\u2013610","DOI":"10.1089\/thy.2014.0335"},{"issue":"10","key":"10_CR90","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1089\/thy.2008.0080","volume":"18","author":"MW Wertenbroek","year":"2008","unstructured":"Wertenbroek MW, Links TP, Prins TR, Plukker JT, van der Jagt EJ, de Jong KP (2008) Radio frequency ablation of hepatic metastases from thyroid carcinoma. Thyroid Official J Am Thyroid Assoc 18(10):1105\u20131110","journal-title":"Thyroid Official J Am Thyroid Assoc"},{"issue":"8","key":"10_CR91","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1210\/jc.2010-1996","volume":"96","author":"JA Wexler","year":"2011","unstructured":"Wexler JA (2011) Approach to the thyroid cancer patient with bone metastases. J Clin Endocrinol Metab 96(8):2296\u20132307","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10_CR92","first-page":"3740","volume":"81","author":"N Wohllk","year":"1996","unstructured":"Wohllk N, Cote GJ, Bugalho MM, Ordonez N, Evans DB, Goepfert H et al (1996) Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 81(10):3740\u20133745","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10_CR93","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/1097-0142(19940115)73:2<432::AID-CNCR2820730231>3.0.CO;2-K","volume":"73","author":"LT Wu","year":"1994","unstructured":"Wu LT, Averbuch SD, Ball DW, de Bustros A, Baylin SB, McGuire WP 3rd (1994) Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Cancer 73(2):432\u2013436","journal-title":"Cancer"},{"key":"10_CR94","doi-asserted-by":"crossref","unstructured":"Yen TW, Shapiro SE, Gagel RF, Sherman SI, Lee JE, Evans DB (2003) Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients. Surgery 134(6):890\u2013899 (discussion 9\u2013901)","DOI":"10.1016\/S0039-6060(03)00408-2"},{"issue":"6","key":"10_CR95","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.surg.2011.09.043","volume":"150","author":"DT Yip","year":"2011","unstructured":"Yip DT, Hassan M, Pazaitou-Panayiotou K, Ruan DT, Gawande AA, Gaz RD et al (2011) Preoperative basal calcitonin and tumor stage correlate with postoperative calcitonin normalization in patients undergoing initial surgical management of medullary thyroid carcinoma. Surgery 150(6):1168\u20131177","journal-title":"Surgery"},{"issue":"10","key":"10_CR96","first-page":"3088","volume":"80","author":"J Zedenius","year":"1995","unstructured":"Zedenius J, Larsson C, Bergholm U, Bovee J, Svensson A, Hallengren B et al (1995) Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 80(10):3088\u20133090","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Recent Results in Cancer Research","Medullary Thyroid Carcinoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-22542-5_10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T17:09:47Z","timestamp":1676480987000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-319-22542-5_10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"ISBN":["9783319225418","9783319225425"],"references-count":96,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-22542-5_10","relation":{},"ISSN":["0080-0015","2197-6767"],"issn-type":[{"value":"0080-0015","type":"print"},{"value":"2197-6767","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]},"assertion":[{"value":"23 October 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}